ArticleBMC women's health2025
Association between lipid accumulation product and visceral adiposity index with endometriosis: evidence from NHANES 1999-2006.
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity has been linked to chronic inflammation and insulin resistance and oxidative stress, which are all associated with the pathogenesis of endometriosis (EMs). This study aimed to investigate the associations between the emerging metabolic markers-lipid accumulation product (LAP) and visceral adiposity index (VAI)-with the EMs.
methodsThis study utilized data from the National Health and Nutrition Examination Surveys (NHANES) 1999-2006. Weighted univariate and multivariate logistics regression models were conducted to explore the associations between LAP and VAI with EMs, with the results expressed as odds ratios (ORs) and 95% confidence intervals (CIs). Moreover, the subgroup analyses based on age, the history of pregnancy, chronic kidney disease (CKD), and female hormones use were further performed to verify whether theses associations remain robust.
resultsTotally 5,188 eligible women were included, with a mean age of 37.19 ± 0.18 years. Among them, 359 (6.92%) had EMs. After adjusted all covariates, we observed both highest LAP and VAI are associated with EMs (LAP: OR = 1.56, 95%CI: 1.02-2.39; VAI: OR = 1.54, 95%CI: 1.09-2.18). Subgroup analyses shown that the associations between LAP and VAI with EMs were more significant among women aged ≥ 35 years, with the female hormones use, with the history of pregnancy, and without the history of CKD.
conclusionWe observed both high LAP and VAI were associated with EMs among reproductive women in the United States. However, further large-scale, well-designed, prospective cohort studies still need in the future to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.